CCIA
EWTX icon

Campbell & Co Investment Adviser’s Edgewise Therapeutics EWTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$968K Buy
+23,829
New +$821K 0.05% 554
2025
Q4 		– Sell
-11,140
Closed -$181K – 1211
2025
Q3 		$181K Sell
11,140
-103,041
-90% -$1.46M 0.01% 1016
2025
Q2 		$1.5M Buy
+114,181
New +$1.65M 0.09% 341

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Campbell & Co Investment Adviser's EWTX Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 23,829 shares worth $968K. The stake represents 0.05% of the portfolio and ranks #554 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in EWTX as recently as Q3 2025.

Campbell & Co Investment Adviser first reported a position in EWTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.5M in Q2 2025. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Campbell & Co Investment Adviser held 23,829 shares of Edgewise Therapeutics worth $968K as of Q2 2026.
  • Edgewise Therapeutics was a new Campbell & Co Investment Adviser position in Q2 2026.
  • Edgewise Therapeutics made up 0.05% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #554 holding.
  • Campbell & Co Investment Adviser first reported a position in Edgewise Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Campbell & Co Investment Adviser's Edgewise Therapeutics position peaked at $1.5M in Q2 2025.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.